These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 7808075)
41. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820 [TBL] [Abstract][Full Text] [Related]
42. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada. Teitel JM; Card R; Strawczynski H Haemophilia; 1998 Sep; 4(5):731-8. PubMed ID: 9873879 [TBL] [Abstract][Full Text] [Related]
43. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate. de Biasi R; Rocino A; Miraglia E; Mastrullo L; Quirino AA Blood; 1991 Oct; 78(8):1919-22. PubMed ID: 1822966 [TBL] [Abstract][Full Text] [Related]
44. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group. Mannucci PM; Brettler DB; Aledort LM; Lusher JM; Abildgaard CF; Schwartz RS; Hurst D Blood; 1994 Apr; 83(7):1958-62. PubMed ID: 7908234 [TBL] [Abstract][Full Text] [Related]
45. Effect of intermediate- and high-purity factor VIII concentrates on immune function in HIV-seropositive haemophiliacs as assessed by quantitative CD 4 counts. Deitcher SR; Tuller J; Dugdale M Haemophilia; 1997 Oct; 3(4):265-9. PubMed ID: 27214862 [TBL] [Abstract][Full Text] [Related]
46. Effect of HIV-1 infection on CD4 cells in a hemophilia cohort. Green D; Deutsche J; Tang M; Goldsmith J Haematologica; 1990; 75 Suppl 5():132-41. PubMed ID: 1982277 [No Abstract] [Full Text] [Related]
47. Changes in T4/T8 ratio over a ten years period related to the factor VIII concentrates used in a group of HIV negative haemophiliacs. Smid WM; van der Meer J; Halie MR Thromb Haemost; 1995 Mar; 73(3):552-3. PubMed ID: 7667844 [No Abstract] [Full Text] [Related]
48. A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. II. Improvements of CD4/CD8 ratio after treatments with heat-inactivated factor concentrates. Shen MC; Hu FC; Lin JS; Tsai W; Fon MF; Wang EC Haemophilia; 1998 Jan; 4(1):33-40. PubMed ID: 9873863 [TBL] [Abstract][Full Text] [Related]
49. Proposed protocol for the evaluation of the effect of high purity factor concentrates on the immune system of hemophilia patients. Brettler DB Thromb Haemost; 1989 Sep; 62(2):811-2. PubMed ID: 2510353 [No Abstract] [Full Text] [Related]
50. [Pathogenesis of peripheral cytopenias in hemophiliac patients]. Magallón M; Bello JL; Herruzo R; Ortega F; Martín Villar J Sangre (Barc); 1989 Oct; 34(5):337-42. PubMed ID: 2515601 [TBL] [Abstract][Full Text] [Related]
51. Immunological alterations in haemophiliacs treated with lyophilized Factor VIII cryoprecipitate from volunteer donors. Ceuppens JL; Vermylen J; Colaert J; Desmyter J; Gautama K; Stevens E; The AL; Vanham G; Vermylen C; Verstraete M Thromb Haemost; 1984 Apr; 51(2):207-11. PubMed ID: 6429883 [TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs. Smid WM; van der Meer J; Halie MR Haemostasis; 1995; 25(5):229-36. PubMed ID: 7489961 [TBL] [Abstract][Full Text] [Related]
54. A comprehensive study of immunological abnormalities in Korean hemophiliacs. Kim KY; Yang CH; Kang SH; Kim DS Yonsei Med J; 1989; 30(2):180-5. PubMed ID: 2508331 [TBL] [Abstract][Full Text] [Related]
56. High purity factor VIII concentrates for the treatment of HIV-positive patients with haemophilia. Sultan Y Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S80-1. PubMed ID: 7495974 [TBL] [Abstract][Full Text] [Related]
57. High frequency of low plasma haptoglobin values found in hemophilia A patients on prophylactic treatment with factor VIII concentrates - a sign of hemolysis? Egberg N; Blombäck M Thromb Haemost; 1981 Aug; 46(2):554-7. PubMed ID: 6795743 [TBL] [Abstract][Full Text] [Related]
58. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study. Goedert JJ; Cohen AR; Kessler CM; Eichinger S; Seremetis SV; Rabkin CS; Yellin FJ; Rosenberg PS; Aledort LM Lancet; 1994 Sep; 344(8925):791-2. PubMed ID: 7916077 [TBL] [Abstract][Full Text] [Related]
59. Influence of plasma source on T-lymphocyte subpopulations in hemophiliacs using factor VIII concentrate. Cable RG; Hoyer L; Marchesi S; Mukherji B; Morse EE; Saxton P N Engl J Med; 1983 Oct; 309(17):1057-8. PubMed ID: 6413860 [No Abstract] [Full Text] [Related]